Colorado diagnostics spin-out MBio raises $6.3m in series B.

MBio Diagnostics, a spin-out of Colorado University at Boulder, has closed a $6.3m series B round.

Backed by private investors, the latest fundraising brings MBio’s total raised to $8.3m, which includes a $2m series A held in 2011.

The company is currently developing a diagnostics kit which offers results on a range of conditions within 20 minutes, including the immune response to tuberculosis.

Chris Myatt, CEO of MBio Diagnostics, said: “MBio aims to be the platform of choice for leading providers and users of clinical and analytical testing services in all market segments from medical and veterinary to food and environmental. This funding allows our team to support existing collaborations and explore new market opportunities across a broad range of industries.”